FGFR1 and uterine cervix neoplasm: The same occurred in the NCI-MATCH (National Cancer Institute-molecular analysis for therapy choice) trial of tumors such as breast, urothelial, and cervical tumors with FGFR1-3 aberrations, as fexagratinib showed modest benefit only in patients with FGFR1-3 point mutations or fusions [52].